Partner Headlines - ANTH

  1. Benzinga's Top #PreMarket Gainers

    Benzinga
  2. Anthera Pharmaceuticals Announces Acquisition of Sollpura For ...

    Benzinga
  3. Hansen Medical Announces Appointment of Chris Lowe as Interim ...

    Benzinga
  4. Anthera Pharmaceuticals Accused of Withholding Data

    Benzinga
  5. Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  6. Benzinga's Microcap Movers for Monday September 17, 2012

    Benzinga
  7. Benzinga's Microcap Movers for Friday August 24, 2012

    Benzinga
  8. Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  9. Anthera Pharmaceuticals Announces Pricing of Public Offering ...

    Benzinga
  10. Benzinga's Microcap Movers for Wednesday July 18, 2012

    Benzinga
  11. Anthera Pharmaceuticals Announces Proposed Public Offering of ...

    Benzinga
  12. Benzinga's Microcap Movers for Tuesday July 17, 2012

    Benzinga
  13. Benzinga's Microcap Movers for Monday July 16, 2012

    Benzinga
  14. Anthera Pharmaceuticals Provides Additional Data from the Recently ...

    Benzinga
  15. Anthera Pharmaceuticals Inc. (ANTH) CEO Paul F Truex buys 20, ...

    GuruFocus
  16. ProShares Trust Ultra VIX Short Term Futures ETF, Nokia Corporation ...

    FoxBusiness
  17. Health Care Sector Wrap

    FoxBusiness
  18. Anthera Pharmaceuticals Down 65% After Reporting Phase 2b PEARL-SC ...

    Benzinga
  19. Benzinga's Top Downgrades

    Benzinga
  20. Anthera Updates Phase 3 Plans

    Benzinga
  21. Benzinga's Microcap Movers for Friday June 15, 2012

    Benzinga
  22. Stock Futures Little Changed Ahead of Data with Morgan Stanley ...

    MarketIntelligenceCenter
  23. UPDATE: Summer Street Research Partners Initiates Buy, $15 PT ...

    Benzinga
  24. Morning Social Media Outlook for Wednesday Feb 22

    Benzinga
  25. Anthera Pharmaceuticals Inc. (ANTH) President and CEO Paul F ...

    GuruFocus
  26. Anthera Announces Completion of Safety Review by DSMB for VISTA-16

    Benzinga
  27. UPDATE: Canaccord Initiates Buy, $13 Target on Anthera Pharmaceuticals

    Benzinga
  28. Canaccord Initiates Anthera Pharmaceuticals at Buy, $13 PT

    Benzinga
Trading Center